Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis
Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis(514 views) Lanzillo R, Di Somma C, Quarantelli M, Gasperi M, Ventrella G, Prinster A, Vacca G, Orefice G, Colao A, Morra VB
Mult Scler (ISSN: 1352-4585, 1477-0970, 1352-4585linking), 2009 Sep; 15(9): 1402-1406.
Keywords: Case-Control Study, Insulin-Like Growth Factor-Binding Protein-3, Multiple Sclerosis, Relapsing-Remitting, Secondary Progressive, Somatomedin Binding Protein 3, Adult, Article, Clinical Assessment Tool, Controlled Study, Disease Activity, Disease Course, Expanded Disability Status Scale, Female, Human, Major Clinical Study, Multiple Sclerosis Severity Scale, Priority Journal, Protein Blood Level, Secondary Progressive Multiple Sclerosis, Age Factors, Case-Control Studies, Insulin-Like Growth Factor Binding Protein 3, Middle Aged, Chronic Progressive, Severity Of Illness Index, Time Factors, Insulin-Like Growth Factor Binding Protein 3 Blood Physiology, Insulin-Like Growth Factor I Analysis Physiology, Chronic Progressive Blood Physiopathology, Relapsing-Remitting Blood Physiopathology,
Affiliations: *** IBB - CNR ***
Neurology, Hermitage Capodimonte Hospital, Naples, Italy
Department of Neurological Sciences, University 'Federico II', Naples, Italy
SDN Foundation, Naples, Italy
Biostructure and Bioimaging Institute, National Research Council, Naples, Italy
Department of Health Science, University of Molise, Contrada Tappino, Campobasso, Italy
Departments of Molecular and Clinical Endocrinology and Oncology, University 'Federico II', Naples, Italy
References: Not available.
Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis
Background: Insulin-like growth factor (IGF)-I has a role in remyelination, and insulin-like growth factor-binding protein-3 (IGFBP-3) might reduce its bioavailability. A role of IGFBP-3 in multiple sclerosis (MS) progression was hypothesized in patients with primary progressive (PP) MS. Objective: To evaluate serum levels of IGF-I and IGFBP-3 in patients with relapsing-remitting (RR) and secondary progressive (SP) MS and their correlations with disease activity and progression. Methods: Sixty-three (41 RR and 22 SP) 'naive' MS patients and 60 age-matched healthy controls were enrolled. Patients were assessed through clinical [Expanded Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), number of relapses] and laboratory investigations. IGF-I and IGFBP-3 were measured by ELISA. Results: Levels of IGF-I and IGFBP-3 were similar in the two MS groups. IGFBP-3 levels were higher in patients with MS than in controls (P
Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis
Serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 in relapsing and secondary progressive multiple sclerosis